Monopar Q4 net loss $5.2M, cash $140.4M; ALXN1840 NDA planned mid-2026

Monopar Therapeutics

Q4 2025 net loss $5.2M ($0.61/sh) vs $10.9M ($2.23) YoY; full-year net loss $13.7M ($1.85/sh) vs $15.6M.
Cash, equivalents and short-term investments $140.4M at Dec 31, 2025, expected to fund operations through Dec 31, 2027.
NDA submission for ALXN1840 (Wilson disease) planned mid-2026; abstracts accepted at EASL 2026 and AAN 2026.
Completed underwritten public offering generating ~$91.9M after concurrent stock repurchase in 2025.
Appointed Susan Rodriguez as Chief Commercial and Strategy Officer for potential ALXN1840 launch.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Monopar Therapeutics reported year ended December 31, 2025 results: net income Net loss for the year ended December 31, 2025, was $13.7 million, or $1.85 per share.

Period: year ended December 31, 2025
Net income: Net loss for the year ended December 31, 2025, was $13.7 million, or $1.85 per share
Result: reported results

Exact text from the filing

Net loss for the year ended December 31, 2025, was $13.7 million, or $1.85 per share

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Monopar Therapeutics reported fourth quarter and full year ended December 31, 2025 results: net income Net loss for the fourth quarter of 2025 was $5.2 million, or $0.61 per share.

Period: fourth quarter and full year ended December 31, 2025
Net income: Net loss for the fourth quarter of 2025 was $5.2 million, or $0.61 per share
Result: reported results

Exact text from the filing

the fourth quarter and full-year 2025 financial results

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Monopar Therapeutics filing history →

Source: SEC EDGAR

accession 0001437749-26-010030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.